Abeona Therapeutics Inc. (ABEO)
Oxford Ledge is still expanding full research coverage of ABEO. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Abeona develops cell and gene therapies, including the FDA-approved ZEVASKYN for genetic skin disease wounds.
SEC filings
- 8-K Shareholder vote results 2026-06-12
- 8-K Departure/election of directors or officers 2026-06-12
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-10
- 8-K Other material event 2026-06-04
- 10-Q Quarterly financial report (unaudited) 2026-05-13
Source: SEC EDGAR.
Annual results
5 years of annual figures for ABEO, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $5.8M | $71.2M | $1.01 |
| 2024 | — | -$63.7M | -$1.55 |
| 2023 | $3.5M | -$54.2M | -$2.53 |
| 2022 | $1.4M | -$39.7M | -$5.53 |
| 2021 | $3.0M | -$84.9M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for ABEO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ABEO in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.